June 26, 2012
The following video is part of our "Motley Fool Conversations" series, in which senior analyst Matt Argersinger and analyst Paul Chi discuss topics across the investing world.
Not many stocks have been spared by the recent market downturn, but Genomic Health continues to trade close to its 52-week high, and for good reason. The small-cap company is a pioneer in the burgeoning field of molecular diagnostics, specifically for cancer screening, and demand for its state-of-the-art tests is growing by leaps and bounds. Genomic's Oncotype breast cancer test, launched in 2004, has become a leading alternative to the standard mammography. In 2010, Genomic launched a test for colon cancer and is in the process of developing tests for prostate and renal cell cancers.
For Genomic Health, the market opportunity is huge. An estimated 1.6 million people in the United States and 12.7 million people worldwide were diagnosed with cancer in just the past year. Get Matt's full take on Genomic Health and why he sees it as a winning value proposition for both cancer patients and investors by watching the video below.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.